ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Revises Application Receipt Dates

November 22, 1985

Phase III Kyprolis Trial Fails OS Primary Endpoint

August 29, 2014

NCI Funds Proteomic Technology Assessment Grants.

September 29, 2006

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

Six Patients Apparently responded To Laetrile, NCI Review Finds; DCT Considers Clinical Trials

September 8, 1978

Information Branches Combined Under ICIC, Moved to Office Of NCI Deputy Director

November 23, 1997